Event-Driven Stocks

Sonoma Pharmaceuticals, Inc.

SNOANasdaq

Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 3 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$14.3M$12.7M$13.3M$12.6M$18.6M$17.9M
Operating income−$3.7M−$4.7M−$4.6M−$5.9M−$3.4M−$7.4M
Net income−$3.5M−$4.8M−$5.2M−$5.1M−$4.0M−$3.3M
Total assets$13.7M$14.7M$16.2M$18.8M$15.0M$14.6M
Total liabilities$9.3M$8.6M$8.3M$10.1M$9.6M$8.9M
Equity$4.4M$6.1M$8.0M$8.7M$5.4M$5.6M
EPS (diluted)$-2.79$-10.63$-1.52$-1.92——
Shares out.1.6M18.8M4.9M3.1M2.1M2.0M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−26.0%
Net margin
−24.2%
Return on equity
−78.4%
Return on assets
−25.2%
Return on capital (ROCE)
−38.7%
Liabilities / assets
67.8%
Debt / equity
2.10×
Book value / share
$2.69
Revenue growth (YoY)
12.2%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-44.32distress
Accruals / assets
−24.6%clean
Beneish M-Score
-4.08normal
Piotroski F-Score
5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 3 warning● 2 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202627,0471.0-96.4%
Apr 30, 2026751,7211.2+4565.6%
Apr 15, 202616,1121.0-58.6%
Mar 31, 202638,9671.0+196.4%
Mar 13, 202613,1451.0+1.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)